Quantcast

Latest Angiotech Pharmaceuticals Inc. Stories

2010-06-10 17:30:00

VANCOUVER, June 10 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced that the company was named a 2010 Medical Device Excellence Award (MDEA) silver award winner for excellence in medical device design for its Quill(TM) Self-Retaining System (SRS). Winning products of the 2010 Medical Device Excellence Awards competition received their awards yesterday, June 9, in a ceremony held during the Medical Design and Manufacturing (MD&M) East 2010...

2010-06-10 13:00:00

VANCOUVER, June 10 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced that its corporate partner, Boston Scientific Corporation (NYSE: BSX), has commercially launched and implanted its first TAXUS(R) Element(TM) Paclitaxel-Eluting Coronary Stent Systems in the European Union and other CE Mark countries. The TAXUS Element Stent System is Boston Scientific's third-generation drug-eluting stent (DES) technology and incorporates a platinum chromium...

2010-05-25 13:00:00

VANCOUVER, May 25 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced Cook Medical, a license holder of Angiotech's paclitaxel technology, presented one-year data at Euro PCR that confirms sustained clinical outcomes with Cook Medical's drug-eluting peripheral stent, Zilver(R) PTX(TM). According to data presented today by Prof. Dierk Scheinert, medical director at Park Hospital Leipzig, 86.2% of all patient subgroups treated with Zilver PTX...

2010-05-04 07:00:00

VANCOUVER, May 4 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced its financial results for the first quarter ended March 31, 2010. "We are pleased to report strong quarterly product sales results, driven primarily by continued growth of our most innovative Proprietary Medical Products," said Dr. William Hunter, President and CEO of Angiotech. "In addition, we are encouraged by sales trends for our Base Medical Products, which showed stability...

2010-05-03 12:00:00

VANCOUVER, May 3 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a specialty pharmaceutical and medical device company, today announced that it has entered into an exclusive distribution agreement with B. Braun for its proprietary Quill(TM) SRS product line in the United Kingdom, Ireland, and France. The term of the distribution agreement will be for five years. According to The Royal College of Surgeons of England, there are approximately 4.2 million...

2010-04-21 12:30:00

European trial explores treating renal artery blockages with a balloon expandable paclitaxel-eluting renal stent VANCOUVER, April 21 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced Cook Medical, a license holder of Angiotech's paclitaxel technology, has enrolled the first patient in its landmark Formula(TM) PTX(R) clinical trial. The trial is the first of its kind to evaluate the safety and effectiveness of a paclitaxel-eluting stent to treat...

2010-04-07 12:00:00

Angiotech acquires manufacturing and intellectual property rights to develop human biological adhesives, hemostats and therapeutic proteins VANCOUVER, April 7 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a specialty pharmaceutical and medical device company, today announced the closing of its acquisition of certain product candidates and technology assets of Haemacure Corporation ("Haemacure"). Haemacure has been involved in proceedings under Canada's...

2010-03-22 06:00:00

TSX:HAE MONTREAL, March 22 /PRNewswire/ - Haemacure Corporation (TSX:HAE) announces that it has obtained authorization from the Superior Court of the Province of Quebec to sell its assets to Angiotech Pharmaceuticals, Inc., a secured creditor of Haemacure. The United States Bankruptcy Court previously authorized the sale to Angiotech of the assets of Haemacure's U.S. subsidiary. The sale of the assets was concluded after a thorough bid-solicitation process carried out on behalf of Haemacure...

2010-03-03 16:00:00

VANCOUVER, March 3 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced its financial results for the fourth quarter and year ended December 31, 2009. "We were pleased to report a particularly strong quarter for product sales, which was driven by the continued strong performance of our Proprietary Medical Products, where we saw sales growth of 53% compared to the same period in 2008," said Dr. William Hunter, President and CEO of Angiotech. "We are...

2009-11-09 06:00:00

VANCOUVER, Nov. 9 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced its financial results for the third quarter ended September 30, 2009. "We were pleased to observe continued strong sales growth in our Proprietary Medical Products business during the quarter, driven primarily by increasing market adoption of our Quill(TM) SRS product line," said Dr. William Hunter, President and CEO of Angiotech. "In addition, our solid early results from our...


Word of the Day
pungle
  • To take pains; labor assiduously with little progress.
This word comes from the Spanish 'pongale,' put it.
Related